Drawing on our executive search practice, we put this together to give employers a grounded, practical view they can act on. A bad executive hire is expensive anywhere, but in medical devices the costs compound in ways they do not in other industries, because the wrong leader can delay a regulatory submission, compromise a quality system, or stall a clinical program. In MedTech, the real cost of a mishire is rarely the severance; it is the time lost in a business where timelines are already long and largely fixed by regulators.
Key Takeaways
- MedTech mishires cost time in a business where timelines are hard to recover.
- Regulatory and clinical delays compound the direct cost of replacement.
- Quality leadership mistakes can create compliance exposure.
- Replacement takes months because the qualified pool is small.
- Rigorous assessment is cheaper than the delay a mishire creates.
Why Time Is the Real Cost
In most industries, a mishired executive costs severance, recruiting fees, and some months of underperformance. In medical devices, the dominant cost is time: a regulatory submission delayed by a quarter, a clinical study designed poorly and needing rework, a product launch that slips past a competitor’s. These delays cannot be recovered by working harder afterward, because the timelines are set by regulatory processes and clinical enrollment, not by internal effort. A year lost to a wrong leader in MedTech is genuinely a year, and in a competitive segment or a capital-constrained company, that can be decisive.
Compounding Effects by Function
The cost profile differs by role. A wrong regulatory leader can misdirect a submission strategy, costing quarters or years. A wrong quality leader can allow system weaknesses that surface in an inspection, with consequences that extend well beyond the person. A wrong clinical leader can design a study that fails to support the claims the company needs, wasting the entire study cost and timeline. A wrong commercial leader in a device company can misjudge reimbursement and market access, stalling revenue after launch. Each of these compounds the direct replacement cost substantially.
The Replacement Lag
Compounding the problem, replacing a MedTech executive takes longer than in most sectors, because the pool of leaders combining regulatory fluency, clinical understanding, and commercial or operational capability is small, and the strongest of them are passive. A company that recognizes a mishire quickly still faces months to find, close, and onboard a replacement, during which the function is under-led. This replacement lag means the total time cost of a MedTech mishire often exceeds a year even when the company acts decisively, which is why avoiding the mishire is so much more valuable than correcting it quickly.
Why Assessment Rigor Pays
Given these costs, the economics of assessment rigor are straightforward: the additional weeks and effort required to assess a MedTech executive properly, probing genuine regulatory judgment, clinical acumen, quality depth, or reimbursement understanding rather than general impressiveness, are trivially cheap against the cost of a wrong hire. Employers who compress assessment to move fast in a competitive market are trading a small time saving for a large risk. The disciplined approach is to move efficiently on process and logistics while refusing to compromise on the depth of the assessment itself.
What This Looks Like in Practice
A device company treats assessment rigor as the cheapest risk control available: it probes genuine regulatory, clinical, quality, or reimbursement judgment rather than general impressiveness, uses sector-credible assessors, and refuses to compress the substance of the evaluation even under time pressure. It moves efficiently on logistics while protecting assessment depth. It does not shortcut evaluation to fill a role quickly, or assume that a strong general executive will grow into MedTech-specific judgment.
The Mistake Employers Keep Making
The most common mistake is compressing assessment to move fast in a competitive market, reasoning that speed matters and the candidate looks strong. In MedTech this trades a few weeks of process for a risk measured in quarters or years of regulatory, clinical, or commercial delay. The company mistakes hiring speed for progress, and a decision made three weeks faster costs a year of timeline when the leader turns out to lack the sector judgment the role required.
Where the Cost of a MedTech Mishire Accumulates
| Cost Component | Why It Compounds in MedTech |
|---|---|
| Regulatory delay | Timelines set externally, cannot be recovered |
| Clinical rework | Study cost and enrollment time both lost |
| Quality exposure | Consequences extend beyond the individual |
| Commercial stall | Reimbursement and access missteps delay revenue |
| Replacement lag | Small talent pool means months to refill |
The Bottom Line
The cost of a bad executive hire in medical devices is dominated by time, regulatory delay, clinical rework, quality exposure, and a long replacement lag in a small talent pool, none of which can be recovered by effort afterward, so invest in genuine sector-specific assessment rigor, which is trivially cheap against the delay a mishire creates. Hire for the specific demands of the situation, and the rest of the leadership equation gets easier.
Related Reading
For more, see Why MedTech Companies Need Specialized Executive Recruiters, Interviewing Medical Device Executives, Onboarding Best Practices for New MedTech C-Suite Hires.
Frequently Asked Questions
- Q: What is the biggest cost of a MedTech mishire?
- A: Time; regulatory delays, clinical rework, and stalled launches cannot be recovered by working harder afterward because the timelines are set externally.
- Q: How long does replacement take?
- A: Typically months, because the pool of leaders combining regulatory fluency, clinical understanding, and commercial capability is small and the strongest candidates are passive.
- Q: Which roles carry the highest mishire cost?
- A: Regulatory (misdirected submission strategy), quality (inspection exposure), clinical (studies that fail to support claims), and commercial (reimbursement and access missteps).
- Q: Is it worth slowing down to assess properly?
- A: Yes; the additional weeks of rigorous assessment are trivially cheap against a mishire that costs quarters or years of timeline in a business where time cannot be recovered.
- Q: How should MedTech assessment differ?
- A: It should probe genuine regulatory judgment, clinical acumen, quality depth, or reimbursement understanding, using sector-credible assessors, rather than general executive impressiveness.
![](https://www.jrgpartners.com/wp-content/uploads/2025/12/tanya-gallardo.jpeg")
Tanya Gallardo
Managing Director, Executive Search & AI Talent Strategy
Tanya Gallardo is the Managing Director of Executive Search & AI Talent Strategy at JRG Partners, leading C-suite and Board engagements across key growth sectors including Technology, Financial Services, and Manufacturing.
With over 18 years of experience specializing in disruptive technology leadership, Tanya is recognized as a leading authority on talent architecture for future-focused executive roles, such as the Chief AI Officer (CAIO) and Chief Digital Officer (CDO). Her expertise lies in accurately assessing the cultural fit and technical depth required to ensure a high return on investment (ROI) for critical leadership appointments.
Prior to her role at JRG Partners, Tanya held senior roles directing global talent acquisition strategies at a major publicly-traded technology firm, advising on organizational design and succession planning for emerging executive functions. She is a recognized speaker and contributor to industry events, sharing data-driven insights on executive compensation, leadership development, and the measurable business impact of C-suite talent.
